BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Vicor Technologies, Inc. Announces Agreement With ZOLL Medical Corporation (ZOLL)


8/3/2011 9:54:12 AM

BOCA RATON, Fla., Aug. 3, 2011 (GLOBE NEWSWIRE) -- David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB:VCRT), today announced that Vicor and ZOLL Medical Corporation (Nasdaq:ZOLL) have entered into a licensing and development agreement. ZOLL Medical Corporation is the leading global manufacturer of resuscitation and critical care devices and related software solutions, including professional defibrillators and automated external defibrillators (AEDs), the LifeVest® Wearable Defibrillator, the AutoPulse® Non-invasive Cardiac Support Pump, and Intravascular Temperature Management (IVTM™) equipment. Vicor Technologies is a biotechnology company focused on the commercialization of its PD2i Analyzer™, an innovative, non-invasive diagnostic employing Vicor's patented, proprietary PD2i® nonlinear algorithm. Clinical use of the PD2i Analyzer™ is supported by an expanding body of literature documenting the PD2i® nonlinear algorithm as a valid metric for risk stratifying specific target populations for future pathological events, including cardiovascular disease patients for death resulting from arrhythmia or congestive heart failure, diabetics for the presence of diabetic autonomic neuropathy (DAN), trauma victims for imminent death absent immediate lifesaving intervention, and ICU patients for mortality risk stratification.

Read at GlobeNewswire

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES